Life Sciences

  • February 19, 2026

    BakerHostetler Adds Contaminants Pro From DLA Piper

    BakerHostetler announced on Thursday that it has brought a San Francisco-based attorney from DLA Piper onto its product liability and toxic tort and environmental teams, calling him "one of the country's leading emerging contaminants litigators."

  • February 18, 2026

    Genetic Testing Co.'s Acquisition Draws Privacy Suit

    Healthcare technology company Tempus AI illegally compelled a genetic testing company to disclose its "massive trove" of genetic data through acquisition and then further disclosed affected individuals' private data to other companies without consent, an Illinois mother told a federal court.

  • February 18, 2026

    Sandoz's Case Against Amgen Over Enbrel Biosimilar Tossed

    A Virginia federal court found that Sandoz Inc. should have brought its claims accusing Amgen of blocking competition for Enbrel in a previous patent dispute over the blockbuster autoimmune disease treatment.

  • February 18, 2026

    Axsome Blocks Sleep Disorder Drug Generic Until 2040

    Biopharmaceutical business Axsome Therapeutics Inc. has inked a deal to end lawsuits against Alkem Laboratories Ltd. over its generic version of a multimillion-dollar drug meant to help people with excessive daytime sleepiness, keeping the generic off the market for years.

  • February 18, 2026

    RFK Jr.-Founded Group Seeks Role In Vaccine Lawsuit

    An organization founded by Robert F. Kennedy Jr. asked a Massachusetts federal judge on Wednesday to let it join the U.S. Department of Health and Human Services secretary as a defendant in a lawsuit challenging recent changes to childhood vaccination schedules so the group can pursue counterclaims against the plaintiffs.

  • February 18, 2026

    NY Judge Trims Umbilical Cord Blood Co. Investor Suit

    A New York federal judge has trimmed a securities class action accusing Global Cord Blood Corp. and others of orchestrating and trying to cover up a scheme in which hundreds of millions of dollars were transferred from Global Cord's cash reserves to its former parent company's founder and other businesses.

  • February 18, 2026

    J&J Unit Appeals $442M Catheter Antitrust Loss To 9th Circ.

    Johnson & Johnson's Biosense Webster health tech unit urged the Ninth Circuit to overturn a California federal jury's $147 million antitrust verdict — later upped to $442 million — over the company withholding cardiac mapping support to hospitals using third-party reprocessed catheters, saying Innovative Health LLC didn't prove its allegations of unlawful tying.

  • February 18, 2026

    FDA Changes Mind, Will Review Moderna MRNA Flu Vaccine

    Moderna on Wednesday said that the U.S. Food and Drug Administration has decided to review its application for its influenza vaccine, a week after the agency refused to consider the application for the new experimental vaccine.

  • February 18, 2026

    Levi & Korsinsky To Lead Novo Nordisk Investor Class Action

    Levi & Korsinsky LLP has been appointed lead counsel in a proposed securities class action accusing Novo Nordisk A/S of misleading investors about its 2025 revenue outlook, after a New Jersey federal judge approved the firm's selection by the investor with the largest financial stake in the case.

  • February 18, 2026

    Paul Hastings Adds Cooley Atty As Life Science Deals Leader

    Paul Hastings LLP announced Wednesday that it has tapped a former Cooley LLP partner and onetime Merck & Co. attorney to chair its life sciences transactions team.

  • February 17, 2026

    Judge Trims Moderna's Defenses In COVID Patent Suit

    A federal judge sitting in Delaware on Tuesday ruled that Moderna could not use obviousness to defend itself from patent claims brought by a rival vaccine developer since it already used that as a defense in related Patent Trial and Review Board proceedings, saying that Moderna had offered expert opinions to support a defense that the patents don't sufficiently teach about the claimed invention.

  • February 17, 2026

    Judge Rips Drugmakers' Borderline 'Disingenuous' Appeal Bid

    A Connecticut federal judge has rejected generic-drug makers' request for a quick appeal of his ruling denying them summary judgment on states' claims they engaged in an "overarching conspiracy" to fix prices, slamming the request for being borderline "disingenuous," mischaracterizing his reasoning and ignoring direct evidence of alleged wrongdoing.

  • February 17, 2026

    Union Says Express Scripts Diverted Billions In Kickback Fees

    A Chicago plumbers union healthcare fund told an Illinois federal court Tuesday that the nation's largest pharmacy benefit manager, Express Scripts, violated federal criminal law when it used a Switzerland-based company to hide kickbacks it generated by charging drug companies fees for key placement on prescription plan drug lists.  

  • February 17, 2026

    Squires Ends IPR After ITC Judge Rejects Validity Challenge

    U.S. Patent and Trademark Office Director John Squires ended a Patent Trial and Appeal Board review of a Hydrafacial LLC skin treatment patent since the same issue had already been adjudicated in the U.S. International Trade Commission.

  • February 17, 2026

    Cohen Milstein To Rep Perrigo Investors In Formula Biz Suit

    Cohen Milstein Sellers & Toll PLLC will represent a proposed class of Perrigo Company PLC investors who allege the company failed to disclose critical issues with infant formula operations that it purchased from Nestlé and caused stock prices to drop as the issues came to light. 

  • February 17, 2026

    McGuireWoods Adds Sidley Private Equity Pro In Los Angeles

    McGuireWoods LLP is expanding its transactional team, announcing Tuesday that it is bringing in a Sidley Austin LLP private equity expert as a partner in its Los Angeles office.

  • February 17, 2026

    J&J Fights Beasley Allen's Bid To Pause Talc DQ Ruling

    A New Jersey state court lacks standing to block an appellate panel's removal of Beasley Allen from representing hundreds of women with ovarian cancer pursuing claims against Johnson & Johnson over talcum powder, the pharmaceutical company has argued in an opposition brief.

  • February 17, 2026

    Edwards Sued In Chancery Over $300M Heart Valve Earn-Out

    The former shareholders of Valtech Cardio Ltd. have sued the company and its parent Edwards Lifesciences Corp. in the Delaware Chancery Court, accusing the medical device giant of deliberately stalling development of a heart valve repair system to avoid paying up to $300 million in earn-out consideration tied to the 2016 acquisition.

  • February 17, 2026

    Philips Settles Suit Over Sleep Machine Starting Home Fire

    Medical equipment company Philips has reached a deal with a woman who alleged in North Carolina federal court that its sleep apnea breathing machine caught fire and caused burns to her mother's face and destroyed her home.

  • February 13, 2026

    RFK Jr. Taps Ex-Jones Day Atty For FDA Senior Counselor

    U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. has named a former Jones Day partner as one of the U.S. Food and Drug Administration's senior counselors, according to an announcement.

  • February 13, 2026

    States' Generic Drugs Antitrust Case Headed Toward Trial

    A Connecticut federal judge has mostly refused to side with pharmaceutical companies facing states' generic drug price-fixing litigation against them, ruling that there are genuine disputes of material fact as to drug distribution chains and the states' antitrust standing and teeing up the case for trial.

  • February 13, 2026

    Chewy Settles Antitrust Claims Over Elanco Flea & Tick Meds

    Chewy has reached a settlement with consumers in a case accusing Elanco Animal Health Inc. of paying several pet supply retailers not to stock generic versions of its Advantix topical flea and tick prevention drugs.

  • February 13, 2026

    Docs Urge Judge To Block CDC's Childhood Vaccine Changes

    Doctors organizations Friday urged a Massachusetts federal judge to stop the government from implementing its new, shorter list of recommended vaccines for children and prevent the next meeting of a committee they say has been tainted by anti-vaccine influence.

  • February 13, 2026

    Reed Smith Nabs Ex-WilmerHale Capital Markets Pro

    Reed Smith LLP has hired a former WilmerHale attorney who specializes in corporate and securities matters as a global corporate group partner in Denver for the firm's business and finance department.

  • February 13, 2026

    Iowa AG Urges 8th Circ. To Unblock Parts Of State PBM Law

    The state of Iowa urged the Eighth Circuit on Friday to lift a preliminary block on parts of a law limiting pharmacy benefit managers' power to set drug prices in the Hawkeye State, arguing a lower court judge erred in holding that parts of the policy were federally preempted.

Expert Analysis

  • AI Scientific Discovery Order Implications For Life Sciences

    Author Photo

    President Donald Trump's November executive order establishing a government effort to use artificial intelligence to accelerate scientific discovery has the potential to leverage significant federal resources and data to support research, drug and device approvals, and AI model training in the life sciences sector, say attorneys at Hogan Lovells.

  • What Rescheduling Means For Cannabis Labels, Marketing

    Author Photo

    The proposed reclassification of cannabis is expected to bring heightened scrutiny of labeling, advertising and marketing from the U.S. Food and Drug Administration and the Federal Trade Commission, but the brands that tighten evidence, standardize operations and professionalize marketing controls now will see fewer surprises and better outcomes, say attorneys at Wilson Elser.

  • Tips From Del. Decision Nixing Major Earnout Damages Award

    Author Photo

    The Delaware Supreme Court recently vacated in part the largest earnout-related damages award in Delaware history, making clear that the implied covenant of good faith and fair dealing cannot be used to rescue parties from drafting choices where the relevant regulatory risk was foreseeable at signing, say attorneys at Sullivan & Cromwell.

  • USPTO's New Patentability Focus Helps Emerging Tech

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to shift patentability criteria back toward traditional standards of novelty, obviousness and adequate disclosure should make it easier for emerging tech, including artificial intelligence, to obtain patents, says Bill Braunlin at Barclay Damon.

  • Malpractice Claim Assignability Continues To Divide Courts

    Author Photo

    Recent decisions from courts across the country demonstrate how different jurisdictions balance competing policy interests in determining whether legal malpractice claims can be assigned, providing a framework to identify when and how to challenge any attempted assignment, says Christopher Blazejewski at Sherin & Lodgen.

  • Courts' Rare Quash Of DOJ Subpoenas Has Lessons For Cos.

    Author Photo

    In a rare move, three federal courts recently quashed or partially quashed expansive U.S. Department of Justice administrative subpoenas issued to providers of gender-affirming care, demonstrating that courts will scrutinize purpose, cabin statutory authority and acknowledge the profound privacy burdens of overbroad government demands for sensitive records, say attorneys at ArentFox Schiff.

  • Unpacking Dormant Commerce Clause Cannabis Circuit Split

    Author Photo

    Federal courts have reached differing conclusions as to whether state-legal cannabis is subject to the dormant commerce clause, with four opinions across three circuit courts in the last year demonstrating the continued salience of the dormant commerce clause debate to the nation's cannabis industry, regulators and policymakers, say attorneys at Perkins Coie.

  • Opinion

    CFIUS Must Adapt To Current Foreign Investment Realities

    Author Photo

    To continue protecting the U.S.’ long-term strategic and economic interests, the Committee on Foreign Investment in the United States should implement practical enhancements that leverage technology, expertise and clear communication, and enable it to keep pace with evolving demands, says attorney Sohan Dasgupta.

  • Utah's AI Prescription Renewal Pilot Could Inform Policy

    Author Photo

    Utah recently became the first state to approve an artificial intelligence system for autonomously renewing certain prescription medicines, providing a test case for how regulators may be able to draw boundaries between administrative automation and medical judgment, say Jashaswi Ghosh at Holon Law Partners and Bryant Godfrey at Foley Hoag.

  • Ramped Up Psychedelic Production Carries Opportunity, Risk

    Author Photo

    Kimberly Chew at Husch Blackwell discusses the key legal implications of the U.S. Drug Enforcement Administration's recent dramatic increases in the production quotas for a range of psychedelic substances, offering guidance on compliance, risk management and strategic opportunities for practitioners navigating this rapidly evolving landscape.

  • Series

    Teaching Logic Makes Me A Better Lawyer

    Author Photo

    Teaching middle and high school students the skills to untangle complicated arguments and identify faulty reasoning has made me reacquaint myself with the defined structure of thought, reminding me why logic should remain foundational in the practice of law, says Tom Barrow at Woods Rogers.

  • New Biotech Nat'l Security Controls May Have Blunted Impact

    Author Photo

    While the newly enacted federal prohibition against contracting with certain biotechnology providers associated with countries of concern may have consequences on U.S. companies' ability to develop drugs, the restrictions may prove to be less problematic for the industry than the significant publicity around their passage would suggest, say attorneys at Wilson Sonsini.

  • From IPR To EPR: The Rapid Rise Of Ex Parte Reexamination

    Author Photo

    With the current administration's dramatic shifts in policy rendering inter partes reviews essentially unavailable for the majority of patents being asserted in litigation, IPR filing rates have plunged, and ex parte reexamination requests have surged to the average rate of IPR petitions in 2024, say attorneys at McKool Smith.

  • Series

    Law School's Missed Lessons: Practicing Resilience

    Author Photo

    Resilience is a skill acquired through daily practices that focus on learning from missteps, recovering quickly without internalizing defeat and moving forward with intention, says Nicholas Meza at Quarles & Brady.

  • Takeaways From The DOJ Fraud Section's 2025 Year In Review

    Author Photo

    Former acting Principal Deputy Chief Sean Tonolli of the U.S. Department of Justice's Fraud Section, now at Cahill Gordon, analyzes key findings from the section’s annual report — including the changes implemented to adapt to the new administration’s priorities — and lays out what to watch for this year.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.